

Index

Locators in **bold** refer to tables; those in *italic* to figures
Abbreviations used in subheadings
BT = botulinum toxin; DBS = deep brain stimulation

- AAA+ ATPases, torsinA
function, 60
abdominal muscles, botulinum
injection, **153t31.1**
abductor hallucis muscle, BT
injection, 148
abductor pollicis muscle, BT
injection, 145
abductor spasmodic dysphonia,
172, 173
BT injections, 174
ablative surgery. *see* stereotactic
ablative surgeries
abobotulinumtoxinA, 99, *115*,
121, 179–80
blepharospasm, 168
cervical dystonia, 160, **162t33.1**
injection schemes, 154
musician's dystonia, 206
potency, 122–23
properties of formulation,
129t27.1
ABTF. *see* antibody-induced
therapy failure
acetylcholine (ACh). *see also*
cholinergic systems
animal models of dystonia, 50
neurotransmitter systems
studies, 38
pathophysiology of
dystonia, 268
acquired dystonia
classification, 12, **12t2.1**
DBS, 234
action-specific dystonia,
temporal patterns, 11
activities of daily living (ADL)
cervical dystonia, 164
DBS, 370, 386
impact of childhood
dystonia, 238
physiotherapy, 247, 266
rating scales, 77, 248–49
AD GCH-1 deficiency, 279–80,
282, **284t55.1**. *see also*
dopa-responsive dystonia;
GCH1 gene
adaptive DBS, future directions
for study, 430
ADCY5 (adenylate cyclase)
gene, 294
adductor brevis muscle, BT
injections, 147
adductor longus muscle, BT
injections, 147
adductor magnus muscle, BT
injections, 147–48
adductor spasmodic dysphonia,
172, 173, 174
adult-onset focal dystonia, 356.
see also focal dystonia
adult-onset idiopathic
blepharospasm, 167
adult-onset spasmodic
dysphonia, 172–73
adverse drug reactions (ADRs),
childhood dystonia, 238. *see*
also side-effects
advocacy, patient, 435–36, 437,
441tIII.2
aetiology
classification (axis II), 3–4, 12,
12t2.1, *13f2.2*
cerebral palsy dystonia, 229
DBS, small children, 238
musician's dystonia, 198–99,
202–05
age at onset
classification of dystonia, 10,
12t2.1
DYT-GNAL, 54
DYT-TOR1A, 53–54
indications for DBS, 352
limb dystonia, 29–30
oromandibular dystonia, 169
primary dystonia, 15–17,
19f3.2
primary late-onset
dystonia, 29–30
psychogenic dystonia, 224
spasmodic dysphonia,
172–73
AIMS (Abnormal Involuntary
Movement Scale), 379–80
akinesia, DBS adverse effects,
397–99, *398f74.1*
alcohol, MR-1-related
paroxysmal
dyskinesias, 292–93
alcohol-responsive dystonia, 368,
442tIII.3
Allan–Herndon–Dudley
syndrome, 294
Allergan. *see*
onabotulinumtoxinA
ALO. *see* apraxia of
eyelid-opening
alternating hemiplegia of
childhood (AHC), 56, 294
amantadine, 281
anaesthesia, paediatric DBS, 240
analgesia, paediatric DBS, 241.
see also botulinum toxin,
analgesic effects
anatomy, muscle. *see* muscular
anatomy
*Anatomy Lesson of Dr. Nicolaes
Tulp*, depictions of
dystonia, 93, *94f20.2*
animal models, 49, 51. *see also*
mouse models
BT therapy, 112, 118
focal hand dystonia, 198
future directions for study, 429
genetics, 49–51
phenotypic models, 51
ANO3 (anoctamin-3, a
transmembrane protein)
gene, 54, **55t10.1**, 60
antecollis, selective peripheral
denervation, 311
antibodies against BT (BTAB),
133, **133t28.1**, 134–35
antibody-induced therapy failure
(ABTF), BT therapy, 133–
35, **133t28.1**, *134f28.1*, 174
anticholinergic agents,
263–64, 268, 270. *see also*
trihexyphenidyl
adverse effects, 269
biperiden, 269–70
for cerebral palsy dystonia, 269
for cervical dystonia, 270
cognitive function, 68–69
diphenhydramine, 263, 270
for dopa-responsive
dystonia, 281
for hemidystonia, 270
history of treatment, 88–90
for Parkinson's disease
dystonia, 270
pathophysiology of
dystonia, 268
for posttraumatic
dystonia, 66
for tremor, 64, 270
antidopaminergic agents, 265
antiepileptic agents, 265, 292
antigen–antibody reactions, BT
therapy, 134
anti-inflammatory effects, BT
therapy, 117
antinociceptive activity, BT
therapy, 115–16. *see also*
botulinum toxin, analgesic
effects
anxiety, 68, 70–71, **70t14.2**
indications for DBS, 353
musician's dystonia, 206–07
psychogenic dystonia, 218
risk factors for dystonia, 257
apomorphine, 264–65
appendicular dystonia, 235
apraxia of eyelid-opening
(ALO), 167, 168, 185–86,
185f38.1, *186f38.2*, *187f38.3*
AR GCH-1 deficiency, 279–80,
282–83, **284t55.1**. *see also*
dopa-responsive dystonia;
GCH1 gene
Arm Dystonia Disability Scale
(ADDS), 77. *see also* limb
dystonia
aromatic acid decarboxylase
(AADC), 279–80, *280f55.1*,
281, 283, **284t55.1**
ARSG (arylsulphatase G) gene,
178, 258

Index

- artistic depictions of dystonia, 92–95
 ‘Anatomy Lesson of Dr. Nicolaes Tulp’ (Rembrandt), 93, **94f20.2**
 ‘De Gaper’ (Brueghel), 92, 94, **95f20.3**
 ‘Character Head’ (Messerschmidt), 94, **95f20.4**
 ‘El patizambo’ (de Ribera), 92–93, **92f20.1**
 artists with dystonia, 94–95
 Asia, BT products, **100t21.1**
 asphyxia, as cause of cerebral palsy dystonia, 229
 assessment scales. *see* rating scales
 athetosis, 1, 2
 ATPases, torsinA function, 60
 ATP1A3 (ATPase Na⁺/K⁺ transporting subunit alpha 3) gene, 51, **55t10.1**, 56, 60, 294. *see also* rapid-onset dystonia-parkinsonism
 atrophy of the basal ganglia and cerebellum (H-ABC), 56
 autoimmune conditions, secondary dystonia, 20–21
 automaticity loss, musician’s dystonia, 198–99
 autosomal dominant GCH-1. *see* AD GCH-1 deficiency
 autosomal recessive GCH-1. *see* AR GCH-1 deficiency
 avoidance behaviour, rehabilitation, 249
 axial dystonia, 3, 157, **159t32.7**, 235
 baclofen
 catheter placement, 231
 cerebral palsy dystonia, 229–31
 clinical effects, 230–31, **230t46.1**
 complications, 231
 dosage, 231
 historical perspectives, 88–90, 264, 302
 overdose syndrome, 231
 small children with dystonia, 239
 withdrawal syndrome, 231
 Baldassare Franceschini. *see* Volterrano
 Barcelona International Dystonia Symposium, 438, **438fII.1**
 basal ganglia dystonias, 32–33, 34, 303, 389, 420. *see also* globus pallidus internus
 DBS, functional mechanisms, 345–46
 future directions for study, 430
 motor network model, 32, **32f6.1**
 as network disorder, 420
 stereotactic surgeries, **317f60.1**
 battery replacements, DBS, 354, 405
 behavioural rehabilitation, focal hand dystonia, 256
 Bell, Sir Charles, 195
 Belzberg, Samuel and Frances, 3, 435
 benign masseter muscle hypertrophy, BT therapy, **116t25.1**
 benzodiazepines, 264
 and cognitive function, 68
 history of treatment, 88–90
 posttraumatic dystonia, 66
 tremor, 64
 Bertrand operation, 300, 306–08, **306f58.1**, **307f58.2**, **308f58.3**, 312, 313
 BFMDRS. *see* Burke–Fahn–Marsden Dystonia Rating Scale
 BH4. *see* tetrahydrobiopterin
 biceps brachii muscle, BT injections, 143, 157–59
 biceps femoris muscle, BT injections, 146
 biofeedback, writer’s cramp, 409–10, **412t77.1**
 biological activity, BT, 130
 biological factors, rehabilitation, 247, 249–50
 bio-psycho-social model, rehabilitation, 247–48, **248t49.1**
 biperiden, 269–70
 bipolar disorder, **70t14.2**
 blepharospasm (BSP), 56. *see also* apraxia of eyelid-opening; Meige syndrome
 age at onset/bodily distribution, 17
 BT therapy, 114–13, 121, 168–69, **168f34.1**
 cannabinoids, 420
 classification, 10, 11
 clinical presentation, 167
 cognitive function, 68
 DBS, 361
 definitions of dystonia, 1, 3
 differential diagnosis, 225
 Dystonia Coalition pilot project, **442tIII.3**
 epidemiology, **28t5.1**, 29
 frontalis suspension operation, 185–86, **186f38.2**, **187f38.3**
 functional imaging, 37
 peripheral trauma, 67
 psychiatric manifestations in dystonia, 70
 rating scales, 77
 risk factors, 30
 secondary dystonia, 20–21
 sleep disturbances, 72
 surgical treatments, 300–01
 treatment (other than BT, DBS), 167, 185
 Blepharospasm Disability Index (BSDI), **76t15.1**, 77
 Blepharospasm Severity Scale, 77
 blink reflex recovery curve, 428
 bodily distribution, classification of dystonia, 10–11, **12t2.1**, 15–17, **19f3.2**
 body awareness training programme, writer’s cramp, 411
 body image, psychiatric manifestations in dystonia, 71
 BOLD (blood oxygen level-dependent) measures, 36. *see also* functional magnetic resonance imaging
 Bonferroni correction, functional imaging, 37
 Botox. *see* onabotulinumtoxinA
 botulinum toxin (BT) therapy, 154. *see also* *Clostridium botulinum* strains; injection schemes; *and see below*
 antinociceptive activity, 115–16
 Asian products, **100t21.1**
 blepharospasm/Meige syndrome, 114–13, 121, 168–69, **168f34.1**
 bruxism, 182–84, **183f37.1**, **184f37.2**
 for cervical dystonia. *see* cervical dystonia, BT therapy
 clinics, 189–92, **191f39.1**
 cognitive function, 68
 composition, 123, 133–34
 development of products worldwide, **101t21.3**
 direct muscle effects, 106, 107
 dosage/dose modifiers, **154t32.1**, 179–80, 183
 DystonieNet recommendations, 444–45
 focal hand dystonias, 179–80
 formulations, 128, **129t27.1**, 160, 206. *see also* abobotulinumtoxinA; incobotulinumtoxinA; onabotulinumtoxinA; rimabotulinumtoxinB
 functional imaging, 37
 future directions for study, 429
 global market for botulinum, 99n*
 historical perspectives, 90, 121–22
 immunology, 133–35, **134f28.1**
 Interdisciplinary Working Group for Movement Disorders: Communication Calendar, **84f17.2**
 mechanism of action, 102–04, **113f24.1**, 116–17, **117f25.1**, 128–30, 206
 musician’s dystonia, 206–09, **207f42.1**, **208f42.2**, **209t42.1**
 new products, **100t21.2**
 oromandibular dystonia, 169–70
 pharmacology, 128–31, **129f27.1**, 133–34
 posttraumatic dystonia, 66, 67
 and rehabilitation, 255
 safety aspects, 120–21, 130–31
 spasmodic dysphonia, 173–74, **174f35.1**, **175f35.2**
 specialist nurses, 85–86
 spinal cord effects, 106–08
 therapeutic failure, 356
 toxin selection, 179–80, 190. *see also* serotypes
 treatment algorithms, 133, 135, 154
 tremor, 64–65
 type B BT, 117–18
 use of non-A/non-B toxins, 137–38
 botulinum toxin, analgesic effects, 115
 antinociceptive activity, 115–16
 mechanism of action, 116–17, **117f25.1**
 preclinical research, 118
 research gaps/needs, 116
 systemic reviews and meta-analyses, 116, **116t25.1**
 type B BT, 117–18
 botulinum toxin, CNS effects
 animal models, 112
 brainstem effects, 108
 clinical contexts, **107f23.1**, 109, 113
 cortical mechanisms, 108–09
 direct effects, 112–13
 molecular mechanisms, **113f24.1**, 116–17, **117f25.1**
 botulinum toxin, commercial manufacture, 120, 126. *see also* *Clostridium botulinum* strains
 chemistry manufacturing and control, 121, 123–24, 125–26
 critical properties, 122–23
 manufacture and approval for commercial use, 123–24
 process validation, 125, 126
 purification, 124–25
 release criteria, 126
 safety aspects, 120–21
 SDS-PAGE method, 120, **120f26.1**, 123
 testing, 126
 botulinum toxin, global markets, 99n*
 Asian products, **100t21.1**
 development of products worldwide, **101t21.3**
 new products, **101t21.3**
 Bouvier, Guy, 313
 brachioradialis muscle, BT injections, 143, 157–59

- bradykinesia, 354, *see also* gait changes
 DBS, 354, 358
 DBS adverse effects, 397, 398–99
 future directions for study, 430
 Braille reading, 409, 431
 brain imaging. *see* imaging
 brain stimulation. *see* deep brain stimulation; transcranial direct current stimulation; transcranial magnetic stimulation
 brain surgery. *see* surgical treatments for dystonia
 BrainFit software, writer's cramp, 411
 brainstem auditory-evoked potentials (BAEPs), 172
 brainstem effects, BT therapy, 108
 Brâncuși, Constantin, 94
 Brandfonbrener, Alice, 196
 brass instrument players, musician's dystonia, 208, 447
 breast implant pain, BT therapy, **116t25.1**
 Brissaud, Édouard, 93
 bromocriptine, 264–65
 Bruegel, Pieter, 92, 94, *95f20.3*
 Brueghel's syndrome, 92
 bruxism, 169, 182–84, *183f37.1*, *184f37.2*
 BSP. *see* blepharospasm
 BTAB. *see* antibodies against BT
 Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS), **76t15.1**
 cerebral palsy dystonia, 229, 378–79
 DBS, 234, 239, 353, 402
 direct cortical stimulation, 336
 Meige syndrome, 360–61
 segmental dystonia, DBS, 357–58
 stereotactic surgeries, 318, 319–21, *321f60.3*
 therapeutic failure in DBS, 392
Caenorhabditis elegans model of dystonia, 49
 caffeine, MR-1-related paroxysmal dyskinesias, 292–93
 calcium ion channels
 intracellular calcium processing, 33
 PRRT2-related paroxysmal dyskinesias, 292
 tremor, 63
 Callot, Jacques, 93
 Canadian Occupational Performance Measure (COPM), 235, 239, 379–80
 cannabinoids, 266, 420–22, *421f79.1*, **422t79.1**
 dosage for musician's dystonia, **422t79.1**
 future directions for study, 430–31
 'Cantigas de Santa Maria', depiction of dystonia, 92
 CAPOS syndrome (cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss), 56
 carbamazepine (CBZ), 292, **293t56.1**
 Career Development Program, Dystonia Coalition, 441, **443tIII.4**
 Caregiver Priorities and Child Health Index of Life with Disabilities Questionnaire, 379
 Carré de Montgeron, Louis Basile, 93
 Castres, Edouard, 93
 catheter placement, intrathecal baclofen, 231
 caudate nucleus, stereotactic surgeries, 315
 causalgia, 21, 67
 CBTXA (botulinum product), 100
 CD. *see* cervical dystonia
 cell banks, *Clostridium botulinum* strains, 124
 cell membranes, 103
 central motor conduction times (CMCT), 239
 central nervous system (CNS). *see also* botulinum toxin, CNS effects
 classification of the dystonias, 12
 lesioning/ablative surgery, 302
 trauma, 66. *see also* posttraumatic dystonia
 cerebellum/cerebellar dystonias, 33
 future directions for DBS study, 430
 motor network model, 32, *32f6.1*
 non-invasive brain stimulation, 417
 cerebral oedema, 66, 366, 400
 cerebral palsy dystonia, 2, 20, 229
 aetiology, 229
 anticholinergic agents, 269
 DBS, 234, 378–81, 382
 intrathecal baclofen, 229–31, **230t46.1**
 pallidotomy outcomes, 319
 prevalence, 30
 rating scales, 229
 wellbeing, 380
 cervical dystonia (CD), 160
 age at onset/bodily distribution, 16, *16f3.1*
 anticholinergic agents for, 270
 bio-psycho-social model, **248t49.1**
 BT therapy. *see below*
 cannabinoids, 420
 classification, 11
 clinical presentation, 247
 DBS, 356–57, 385–86
 definitions of dystonia, 1
 DystonieNet approach, 444–45
 epidemiology, **28t5.1**, 29
 functional imaging, 37
 future directions for study, 430
 pain, 72
 peripheral denervation, 310–13, **311t59.1**, *313f59.1*
 peripheral neurotomy, 306–08, *306f58.1*, *307f58.2*, *308f58.3*
 peripheral trauma, 67
 rating scales, 77
 rehabilitation, 252–55, *253f50.1*, *254f50.2*
 risk factors, 30
 spinal cord stimulation, 301
 stereotactic surgeries, 321
 surgical treatments, 299, 300
 cervical dystonia, BT therapy, 116, 160
 efficacy, 161
 formulations, 160
 future directions for study, 163–64
 injection schemes, 154–55
 RCTs, **162t33.1**
 side-effects, 161
 suboptimal responses/non-responders, 161–63, *163f33.1*
 treatment principles, 160–61
 ultrasonography targets, 150–51, *152f31.3*
 Cervical Dystonia Impact Profile (CDIP-58), **76t15.1**, 77, 80
 CFCS. *see* Communication Function Classification System
 CGI scale (Clinical Global Impression Scale), 380
Changing Keys: Billy McLaughlin and the Mysteries of Dystonia film, 436
 Charcot, J.-M. 93, 217
 chemistry manufacturing and control (CMC), BT products, 121, 123–24, 125–26
 children with dystonia. *see* paediatric dystonia
 choking under pressure, musician's dystonia, 202, 203, 204
 cholinergic systems. *see also* acetylcholine
 BT, 102, 103, 115, 129, 137–38
 future directions for study, 429
 neurotransmitter systems studies, 38
 nuclear membrane budding, 60
 pathophysiology of dystonia, 268
 choreoathetosis. *see* cerebral palsy dystonia
 CIZ1 (Cip1-interacting zinc finger protein) gene, 54, **55t10.1**, 60
 classical test theory (CTT), 79, 80
 classification of dystonias, 3–4, 9, 13–14
 aetiology (axis II), 12, *13f2.2*
 clinical features (axis I), 3–4, 10–12, *11f2.1*
 current classification, 3–4, 10, **12t2.1**
 and genetics, 53, *54f10.1*, **55t10.1**
 historical perspectives, 9
 secondary dystonia, 9–10, 13, 20, **21t4.3**
 unresolved issues with earlier classifications, 9–10
 clinical features (axis I), classification of dystonia, 3–4, 10–12, *11f2.1*, **12t2.1**
 Clinical Global Impression Scale (CGI), 380
 clinical outcome assessments (COAs), 79
 classical test theory, 79
 comparison of methods, 80
 content validity, 80
 future directions for study, 430
 Rasch measurement theory, 79–80
 systematic review of research, 80
 clinics, botulinum toxin (BT) therapy, 189–92, *191f39.1*
 cloneazepam, 66, 90
Clostridium botulinum strains, 102, 120, 123–24, 125, **129t27.1**. *see also* botulinum toxin therapy
 clozapine, 265, 372
 'The clubfooted boy', artistic depictions, 92–93, *92f20.1*
 CMC. *see* chemistry manufacturing and control
 CMCs (central motor conduction times), 239
 COAs. *see* clinical outcome assessments
 cochlear implantation in children, lessons for DBS, 241–42
 coffee, MR-1-related paroxysmal dyskinesias, 292–93
 cognitive factors, indications for DBS, 353
 cognitive function, 68–70, **69t14.1**
 DBS outcomes, 239, 386
 and rehabilitation, 257
 COL6A3 (collagen type VI $\alpha 3$ chain) gene, 54, **55t10.1**
 combination drug treatments, 266

Index

- combined dystonia
 classification, 11
 genetics, 55–56, **55t10.1**
 therapeutic failure in DBS, 394
 Communication Calendar (CC),
84f17.2
 Communication Function
 Classification System
 (CFCS), 229
 complex dystonias, genetics,
55t10.1
 complex interventions (CI),
 writer's cramp, 411
 complex regional pain syndrome
 (CRPS), 21, 67
 complexing proteins, 90, 123,
 128, 133–34
 computerised memory training,
 writer's cramp, 411
 COMT (catechol-O-methyl
 transferase) inhibitors, 281
 conditional knockout
 rodent models, DYT1
 dystonia, 50–51
 constraint-induced training,
 musician's dystonia, 210
 construct validity, assessment
 scales, 75
 content validity, assessment
 scales, 75, 80
 content validity ratio (CVR),
 assessment scales, 75
 COPM. *see* Canadian
 Occupational Performance
 Measure
 corrective muscles,
 rehabilitation, 254, *254f50.2*
 corrugator supercilii muscle, BT
 injections, 139
 cortical mechanisms, BT
 therapy, 108–09
 cortical silent period (CSP),
 41, 414. *see also* inhibition
 systems
 cortical stimulation. *see* direct
 cortical stimulation
 corticobasalganglionic
 degeneration, 3
 cranial dystonia. *see also*
 blepharospasm; laryngeal
 dystonia; Meige syndrome;
 oromandibular dystonia
 age at onset/bodily
 distribution, 16–17
 BT therapy, 114–13, 150–51,
 155, **156–55**, *168f34.1*
 definitions, 1
 Craniocervical Dystonia
 Questionnaire (CDQ-24),
76t15.1, 357
 cricoarytenoid muscle, abductor
 spasmodic dysphonia, 174
 'The crippled boy', artistic
 depictions, 93
 Cronbach's alpha, assessment
 scales, 75
 CRPS. *see* complex regional pain
 syndrome
 Cruchet, Rene, 87, *88f19.1*
 crude prevalence rates (CPR),
 primary dystonia, 27, **28t5.1**
 CTT (classical test theory), 79, 80
 culture media, BT products, 124
 David Marsden Award, 438
 DASH. *see* Disability of Arm,
 Shoulder and Hand scale
 DC. *see* Dystonia Coalition
 DCS. *see* direct cortical
 stimulation
 DDS (Dystonia Discomfort
 Scale), 160
 'De Gaper' (Yawning Man),
 depiction of dystonia, 92
 deep brain stimulation (DBS),
 302–03, 345. *see also*
 globus pallidus internus
 DBS; subthalamic nucleus
 DBS; thalamic DBS; *and*
see below
 adverse effects/side-effects,
 354, 361, 386, 397–99,
398f74.1, 405
 basal ganglia activity, 345–46
 basal ganglia
 pathophysiology, 345
 blepharospasm, 167
 cerebral palsy dystonia,
 378–81, 382
 cervical dystonia, 356–57
 cognitive function, 68–69
 complications, 386, 404–06
 future directions for
 study, 429–30
 and genetics, 56
 historical perspectives, 90,
 302–03, 389
 inhibition systems, 347–48
 isolated dystonia, 352–54,
 356–58
 long-term effects, 347–48, 386
 mechanism of action, 348–49,
 369
 Meige syndrome, 360–61
 myoclonus dystonia
 syndrome, 368–70
 other secondary
 dystonias, 382–84
 outcomes, 353–54, 360–61,
 380, 386
 paediatric. *see below*
 plasticity changes, 235, 345,
 347–48
 postoperative
 programming, 370
 posttraumatic dystonia, 66,
 382
 programming, 400–02
 psychiatric manifestations in
 dystonia, 71
 safety aspects, 373
 segmental dystonia, 357–58
 short-term effects, 347
 stimulation parameters, 386,
 400–01, 405
 surgical technique, 369–70
 tardive dyskinesia/tardive
 dystonia, 372–75, **374t68.1**
 timing/frequency of
 treatment, 380–81
 tremor, 65
 deep brain stimulation,
 paediatric dystonia, 233,
 235–36
 acquired dystonia, 234
 anaesthesia, 240
 analgesia, postoperative, 241
 battery replacements, 354
 brain targets, 233, 240
 cerebral palsy dystonia, 234
 cognitive function, 239
 DBS settings, 233–34
 globus pallidus internus
 volume, 239
 head growth, 240
 head shape, 240
 implantable pulse generators,
 241, *241f48.1*
 indications/patient selection
 criteria, 233
 isolated dystonia, 234
 medication weaning, 354
 multiple electrodes/ combined
 DBS, 235
 myoclonus dystonia
 syndrome, 369
 neurodegeneration with brain
 iron accumulation, 234
 other target symptoms, 235
 proportion of life lived with
 dystonia, 239
 rating scales, 239
 small children, 239–42,
241f48.1
 status dystonicus, 234–35
 technical considerations in
 small children, 239–41
 wound closure, 241
 deep brain stimulation,
 therapeutic failure, 392
 flow chart of diagnostic/
 therapeutic measures,
395f73.2
 future directions for study, 430
 hardware problems, 392–94,
393f73.1
 programming, 402
 pseudo-failure, 394
 definitions
 antibody-induced therapy
 failure, **133t28.1**
 dystonia, 1–3, *2f1.1*, 9, 10, 178
 DRD-plus, 279
 psychogenic dystonia, 217–18
 segmental dystonia, 357
 therapeutic failure in
 DBS, 392
 deformities, musculoskeletal,
 238
 degenerative conditions. *see*
 neurodegenerative disease
 della Francesca, Piero, 93
 Delphi method, assessment
 scales, 75
 denervation, peripheral. *see*
 intradural denervation/
 intradural rhizotomy;
 selective peripheral
 denervation
 Denny-Brown, D. 3
 dentato-rubro-pallido-luysian
 atrophy (DRPLA), 24
 depression, 17, 68, 70–71,
70t14.2
 DBS complications, 405
 DBS indications, 353
 psychogenic dystonia, 217
 subthalamic nucleus DBS
 target, 386
 depressor angularis oris muscle,
 BT injections, 140, 155
 depressor labii inferioris muscle,
 BT injections, 140
 depressor supercilii muscle, BT
 injections, 140
 developmental implications,
 childhood dystonia, 238
 DHPR deficiency. *see*
 dihydropteridine reductase
 deficiency
 diagnosis/differential diagnosis,
 436. *see also* DSM
 essential tremor, 64
 and genetics, 56
 oromandibular dystonia, 169
 primary dystonia, **15t3.1**
 psychiatric manifestations in
 dystonia, 70
 psychogenic dystonia, 217,
 218–20, **219t44.1**, 221,
 224–25
 and rehabilitation, 247
 small children with
 dystonia, 239
 spasmodic dysphonia, 173
 differential learning (DL), focal
 hand dystonia, 257–58, 259
 diffuse brain disorder, secondary
 dystonia, 20, **21t4.3**
 digastric muscle, BT
 injections, 141
 dihydropteridine reductase
 (DHPR) deficiency,
 279–80, *280f55.1*, 282–83,
284t55.1
 diphenhydramine, 263, 270
 direct cortical stimulation
 (DCS), 335, 338–40
 DASH scale, 336, **339t61.3**
 motor cortex, 336–38,
337f61.1, **337t61.1**,
338f61.2, **338t61.2**,
339f61.3
 premotor cortex, 336
 surgical procedure, 335
 DIS (Dyskinesia Impairment
 Scale), 229
 Disability of Arm, Shoulder and
 Hand (DASH) scale, 336,
339t61.3
 disfigurement, psychiatric
 manifestations in dystonia, 71

- distractibility, psychogenic dystonia, 220, 224
 diurnal fluctuations, dystonia symptoms, 11
 DMRF. *see* Dystonia Medical Research Foundation
 dopamine receptor agonists, 264–65
 dopamine receptor antagonists, 88–90, 272, 273f4.2, 274. *see also* tetrabenazine
 dopaminergic neurons, animal models of dystonia, 50
 dopaminergic system, future directions for study, 427
 dopaminergic transmission, neurotransmitters, 38
 dopa-responsive dystonia (DRD), 22, 427
 aetiology, 263
 animal models of dystonia, 51
 cognitive function, 69
 diagnostic/therapeutic implications, 56
 drug treatment. *see below*
 genetics. *see* *GCH1* gene
 genomics, 59
 neurotransmitter deficiencies, 279–80, 280f5.1, 282–83
 psychiatric manifestations, 70t14.2, 71
 dopa-responsive dystonia, drugs for, 264–65, 279, 280–82, 284t55.1. *see also* levodopa
 pregnancy, 283
 tetrahydrobiopterin, 279–80, 281, 282–83, 284t55.1
 treatment principles, 279–80
 dorsal premotor cortex (PMd), non-invasive brain stimulation, 415–17
 double task activities, rehabilitation, 255
 Drachman, Daniel, 121
 dramatising behaviours, psychogenic dystonia, 220–21
 DRD. *see* dopa-responsive dystonia
 DRD-plus, 279, 280–82, 283, 284t55.1
Drosophila melanogaster models, 49, 60
 DRPLA (dentato-rubro-pallidoluysian atrophy), 24
 drugs. *see* pharmaceuticals
 DSM (*Diagnostic and Statistical Manual*) diagnostic criteria
 psychiatric manifestations in dystonia, 70
 psychogenic dystonia, 218, 221
 DSNs (dystonia specialist nurses), 85–86
 duration of dystonia. *see* symptom duration
 dynamic stereotypes, musician's dystonia, 202–03, 204
 dynamic systems theory, musician's dystonia, 258–59
 dysbasia lordotica progressiva, 1
 Dyskinesia Impairment Scale (DIS), 229
 dyskinetic cerebral palsy. *see* cerebral palsy dystonia
 Dysport. *see* abobotulinumtoxinA
 dystonia
 classification, 3–4
 definitions, 1–3, 2f1.1, 9, 10
 heterogeneity, 380, 390, 400, 404, 428
 Dystonia Advocacy Network (DAN), 435–36
 Dystonia Coalition (DC), 440n*
 Career Development Program, 441, 443tIII.4
 meetings/seminars, 442
 participating organisations/centres, 441tIII.1
 patient advocacy groups, 441tIII.2
 Pilot Project Program, 441, 442tIII.3
 programmes and projects, 440–42
 Dystonia Discomfort Scale (DDS), 160
 Dystonia Europe (DE), 437–39
 Dystonia Medical Research Foundation (DMRF), 1, 3, 435–36
 future directions for study, 436
 public awareness, 436
 stimulating research, 435
 website, 447
Dystonia Moves Me campaign, 436
 dystonia musculorum deformans, 1, 2, 9, 15
 Dystonia Society UK, 86
 dystonia specialist nurses (DSNs), 85–86
Dystonia Stories (Dystonia Europe), 439
 dystonia-myoclonus. *see* myoclonus-dystonia
 dystonia-plus syndromes, 20, 22
 dystonic camptocormia. *see* writer's cramp
 dystonic fingerprints, 20
 dystonic postures, 310–11
 dystonic tremor. *see* tremor
 DystonieNet approach, cervical dystonia, 444–45
 BT therapy recommendations, 444–45
 participating organisations/centres, 445fIV.1
 physical therapy recommendations, 445
 DYTn system, 53. *see also below*
 classification of dystonia, 9, 10, 12, 13f2.2
 motor network model, 34
 primary dystonia, 15, 18t3.2
 DYT1 dystonia
 animal models of dystonia, 49–51
 cognitive function, 69t14.1
 DBS, paediatric dystonia, 234
 diagnosis, 56
 Dystonia Coalition pilot project, 442tIII.3
 focal hand dystonia, 178
 functional imaging, 37
 genetics, 37, 53–54, 55t10.1, 60, 268, 427
 genomics, 59
 novel therapeutics, 61
 pathophysiology, 268
 proteomics, 60–61, 61f11.1
 psychiatric manifestations, 70t14.2
 stereotactic surgeries, 320
 tremor, 63
 DYT2 dystonia, 53
 DYT3 dystonia, 55t10.1, 56, 59
 DYT4 dystonia, 55t10.1, 56, 59
 DYT5 dystonia. *see* dopa-responsive dystonia
 DYT6 dystonia
 DBS, paediatric dystonia, 234
 Dystonia Coalition pilot project, 442tIII.3
 functional imaging, 37
 genetics, 37, 54, 55t10.1, 234, 442tIII.3
 genomics, 59
 DYT7 dystonia, 53, 178
 DYT11 dystonia. *see* myoclonus-dystonia
 DYT12. *see* rapid-onset dystonia-parkinsonism
 DYT13 dystonia, 53, 178
 DYT16 dystonia, 55t10.1, 56
 DYT23 dystonia, 54, 55t10.1, 60
 DYT24 dystonia, 54, 55t10.1, 60
 DYT25 dystonia, 54, 55t10.1, 60
 early-onset, generalised dystonia, 55t10.1. *see also* DYT1 dystonia
 education of healthcare providers, 250, 437
 education of patients. *see* patient education
 EFNS/MDS-ES Task Force, 264
 'El patizambo' (The clubfootedboy), artistic depictions, 92–93, 92f20.1
 electromyography (EMG)
 BT therapy, 154, 163–64, 172
 selective peripheral denervation, 311
 spasmodic dysphonia, 172, 174f35.1
 writer's cramp, biofeedback, 409–10
 electrophysiological treatments, 224–25, 431. *see also* transcranial direct current stimulation; transcranial magnetic stimulation
 electrotherapy, history of treatment, 87, 89f19.2
 embouchure dystonia, 94, 197–98, 203, 422
 BT therapy, 208
 cannabinoids, 422
 pedagogical retraining, 211
 EMG. *see* electromyography
 encephalitis, 2, 319
 environmental risk factors. *see* risk factors
 enzymatic activity, BT, 103–04
 enzyme deficiencies. *see* neurotransmitter/enzyme deficiencies
Epidemiological Study of Dystonia in Europe (Marsden and Warner), 437
 epidemiology, 27, 30
 BT therapy, 134
 botulism, 102
 focal hand dystonia, 178–79
 primary dystonia, 27, 28t5.1
 primary early-onset dystonia, 27
 primary late-onset dystonia, 29–30
 psychogenic dystonia, 218
 secondary dystonia, 30
 small children with dystonia, 238
 spasmodic dysphonia, 172
 tardive dyskinesia and tardive dystonia, 372
 tremor, 63
 EPS. *see* extrapyramidal motor system
 ER-associated protein degradation (ERAD) pathway, 60
 ergonomic devices, writer's cramp, 411, 412f77.2
 essential blepharospasm, 167
 essential tremor (ET), 63–65. *see also* tremor
 European Brain Council, 437
 European Dystonia Research Network, 438, 439fII.2
 European Federation of Neurological Associations (EFNA), 9, 437
 evolutionary perspectives, finger movement, 199, 199f40.3
 excipients, BT, 100t21.1, 100t21.2, 123, 125, 128, 129t27.1, 133–34
 executive function. *see* cognitive function
 exercise progression, 254, 255. *see also* rehabilitation
 expectations, patient, DBS complications, 405–06
 extension (retrocollis), 311

Index

- extensor carpi radialis muscles, BT injections, 143, 155–56
 extensor carpi ulnaris muscle, BT injections, 143–44, 155–56
 extensor digitorum muscle, 144, 148, **153t31.1**
 extensor hallucis longus muscle, BT injections, 148, **153t31.1**
 extensor indicis muscle, BT injections, 144, 155–56
 extensor pollicis longus muscle, BT injections, 144
 extrapyramidal motor system (EPS), 2, 20, 172, 315. *see also* caudate nucleus; globus pallidus internus
 eye of the tiger sign, 24, 383, 384
 eyelid opening apraxia. *see* apraxia of eyelid-opening
 eye–neck coordination, cervical dystonia, 253
- facial muscles, BT injections, 139–41, **153t31.1**
 Fahn, Stanley, 2, 447
 classification of dystonia, 3, 9
 definitions of dystonia, 3
 Fahn–Marsden dystonia rating scale (F-M), 76–77. *see also* Burke–Fahn–Marsden Dystonia Rating Scale
 fatigue
 musician's dystonia, 202
 and rehabilitation, 249
 female gender. *see* gender
 fermentation parameters, BT products, 124
 FHD. *see* focal hand dystonia
 finger splinting. *see also* immobilisation techniques
 focal hand dystonia, 256–57
 musician's dystonia, 210
 writer's cramp, 410, *410f77.1*, **412t77.1**
 fingerprints, dystonic, 20
 fitness exercises, writer's cramp, 411. *see also* rehabilitation
 fixed dystonia
 direct cortical stimulation, 336–38, **337t61.1**
 therapeutic failure in DBS, 394, 395
 5-HTP, dopa-responsive dystonia, 281–82, **284t55.1**
 Fleisher, Leon, 95, 195, 196, 446–47
 flexed position of the neck (antecollis), 311
 flexibility, dynamic systems theory, 258–59
 flexion patterns
 musician's dystonia, 196–97
 writer's cramp, *178f36.1*
 flexor carpi radialis muscle, BT injections, 144, 157–59
 flexor carpi ulnaris muscle, BT injections, 144, *150f31.1*, 155–56, 157–59
 flexor digitorum muscles, BT injections, 148, *150f31.1*, **153t31.1**
 flexor digitorum profundus muscle, BT injections, 144, *150f31.1*
 flexor digitorum superficialis muscle, BT injections, 144–45
 flexor hallucis longus muscle, BT injections, 148
 flexor pollicis brevis muscle, BT injections, 145
 flexor pollicis longus muscle, BT injections, 145, *150f31.1*, 155–56
 F-M scale. *see* Fahn–Marsden dystonia rating scale
 fMRI. *see* functional magnetic resonance imaging
 focal brain lesions, secondary dystonia, 20, **21t4.3**
 focal dystonia. *see also* blepharospasm; cervical dystonia; cranial dystonia; laryngeal dystonia; oromandibular dystonia; spasmodic dysphonia; writer's cramp
 age at onset/bodily distribution, 15–16
 artists with dystonia, 95
 classification, 11
 DBS, 356–57
 definitions of dystonia, 1
 Dystonia Coalition pilot project, **442tIII.3**
 epidemiology, **28t5.1**, 29–30
 examples, *16f3.1*
 idiopathic dystonia, *16f3.1*
 musician's dystonia, 203
 peripheral trauma, 67
 stereotactic surgeries, 320–21
 focal hand dystonia (FHD), 178, 180. *see also* musician's dystonia; writer's cramp
 aetiology, 178
 animal models, 198
 BT therapy, 179–80
 cannabinoids, *421f79.1*
 clinical presentation, 247
 components, *364f66.1*
 epidemiology, 178–79
 historical perspectives, 363
 indications/patient selection criteria, 363–64
 musician's dystonia, 203
 non-invasive brain stimulation, 414–17, **416t78.1**
 pathophysiology, 178–79
 psycho-social factors, 248
 rehabilitation, 256–59, *257f51.1*
 stereotactic surgeries, 320–21, 363, *365f66.3*. *see also* thalamotomy
 surgical technique, 364
 symptoms/natural history, 178
 treatment (other than BT therapy), 179
 focal task-specific dystonia of musicians. *see* musician's dystonia
 dopa-responsive dystonia, **284t55.1**
 formalin test, 117, 118
 fractional anisotropy (FA), children with dystonia, 239
Freedom to Play public awareness campaign, 196
 Friedrich's ataxia, 24
 frontalis muscle, BT injections, 139, 155
 frontalis suspension operation (FSO), blepharospasm, 185–86, *186f38.2*, *187f38.3*
 Frucht, Steven, 447
 functional imaging, 36, 38–39
 neurotransmitter systems studies, 38
 pathophysiology, 40
 resting state PET studies, 37
 task-based studies, 37–38
 functional magnetic resonance imaging (MRI), 36
 direct cortical stimulation, 335, *339f61.3*
 pathophysiology, 45
 functional/psychogenic dystonia (F/PDys), 217, 221
 association with peripheral injury, 221, **222t44.2**
 clinical assessment, 218
 clinical features, 224
 diagnosis/differential diagnosis, 218–20, **219t44.1**, 221, 224–25
 electrophysiologic testing, 224–25
 epidemiology, 218
 future directions for study, 428
 historical perspectives, 217
 physical examination, **219t44.1**, 220–21
 psychiatric history, 220
 terminology, 217–18
 functional severity ratings, cerebral palsy dystonia, 229
 funding, research, 448–49
 future directions for study, 427
 animal models, 429
 basal ganglia dystonias, 430
 bradykinesia, 430
 BT therapy, 429
 cannabinoid therapy, 430–31
 cerebellar dystonias, 430
 cervical dystonia, 163–64, 430
 DBS, 163–64, 429–30
 dopaminergic system, 427
 drugs/pharmaceuticals, 430–31
 Dystonia Coalition role, 442–43
 Dystonia Medical Research Foundation role, 435, 436
 DystonieNet
 recommendations, 445
 DYT1 dystonia, 61
 electrophysiological treatments, 431
 functional dystonia, 428
 funding, 448–49
 genome-wide association studies, 427
 genetics, 427–28
 inhibition systems, 428, 430
 limb dystonia, 431
 neurophysiology, 428–29
 outcome assessment, 430
 placebo effect, 431
 rehabilitation, 431
 SSRIs, 430–31
 surgical treatments, 429–30
- GAG (group-specific antigen) gene, 71
 gait changes, 398, 430. *see also* bradykinesia; hypokinesia
 galactosemia, herodegenerative dystonia, 23
 gamma-aminobutyric acid (GABA)
 neurotransmitter systems studies, 38
 non-invasive brain stimulation, 414–15
 pharmacology, 45, 88–90, 230, 264. *see also* baclofen
 gamma hydroxybutyric acid, 264
 gamma knife radiosurgery, 326
 Garcia-Ruiz, Jose, 92
 gastrocnemius muscle, BT injections, 147, **153t31.1**
 Gaucher's disease, 23
 GCH1 (GTP cyclohydrolase) gene, 53, 55, **55t10.1**, 59, 427. *see also* dopa-responsive dystonia
 animal models of dystonia, 51
 paroxysmal exercise-induced dyskinesias, 293–94
 gender differences in dystonia
 dopa-responsive dystonia, drug treatment, 283
 focal hand dystonia, 178–79
 limb dystonia, 29–30
 Meige syndrome, 360
 musician's dystonia, 195, 199, 258–59
 oromandibular dystonia, 169
 psychogenic dystonia, 224
 spasmodic dysphonia, 172
 genetic pleiotropy, 238
 genetics, 10, 53, 56. *see also specific genes*
 and classification, 53, *54f10.1*, **55t10.1**. *see also* DYTn system
 combined dystonia, 55–56, **55t10.1**
 diagnostic/therapeutic implications, 56
 dynamic systems theory, 258

- Dystonia Coalition pilot project, **442tIII.3**
 focal hand dystonia, 178
 future directions for study, 427–28
 indications for DBS, 353
 isolated dystonia, 17, **18t3.2**, 53–54, **55t10.1**
 myoclonus dystonia syndrome, 368
 primary dystonia, 17, **18t3.2**
 primary late-onset dystonia risk factors, 30
 genome-wide association studies (GWAS), 427
 genomics, 59–60
 genotypes. *see also* DYTn system
 animal models of dystonia, 49–51
 classification of dystonia, **13f2.2**
 primary dystonia, 17, **19f3.2**
 German Registry for DBS in Paediatric Movement Disorders (GEPESTIM), 384
 geste antagoniste. *see* sensory trick circuits
 Global Dystonia Rating scale (GDS), 76, 318
 globus pallidus internus (GPI), stereotactic surgeries, 315–16, **317f60.1**, 323. *see also* pallidotomy
 globus pallidus internus DBS, 345, 353, 354, 389
 adverse effects, 397–99, **398f74.1**
 cervical dystonia, 356–57
 functional mechanisms, 346–47
 future directions for study, 430
 historical perspectives, 302, 303
 Meige syndrome, 361
 modulation of pallidal activity, 346–47
 myoclonus dystonia syndrome, 368–69
 paediatric dystonia, 233, 239, 240
 programming, 400–02
 segmental dystonia, 357–58
 treatment failure, 386
 GLUT1. *see* SLC2A1 gene
 glutamate system, BT therapy, 117
 glutaric acidemia/aciduria, 23, 319
 gluteus maximus muscle, BT injections, 146, **153t31.1**
 gluteus medius muscle, BT injections, 146, **153t31.1**
 GM1-gangliosidosis, 23
 GNAL (guanine nucleotide-binding protein) gene, 54, **55t10.1**, 60
 Goal Attainment Scale (GAS), 235, 248–49, 380
 goal-setting, rehabilitation, 249–50
 Gowers, W. R. 195, 198, 200
 gracilis muscle, BT injections, 146, **153t31.1**
 Graffman, Gary, 195, 446
 grey matter lesions, children with dystonia, 238–39
 Gross Motor Function Classification System (GMFCS), 229
 guidelines, dystonia
 Dystonia Coalition pilot project, **442tIII.3**
 Dystonia Europe, 438
 guitarists, musician's dystonia, 212
 H (Hoffmann's) reflex, 40
 HAGH (hydroxyacylglutathione hydrolase) gene, 293
 Hall, Ivan C. 124
 Hallervorden-Spatz disease, 24, 319
 Hamburg Dystonia Europe meeting, 438
 hand dystonia. *see* focal hand dystonia
 hand muscles, BT injections, **153t31.1**
 handwriting changes, DBS adverse effects, 397–98, **398f74.1**
 handwriting training, writer's cramp, 410–11
 Hannover *Treatment of Dystonia* congresses, 438
 haptics, learning-based sensorimotor training, 210
 hardware, DBS, 392–94, **393f73.1**, 400, 404–05
 Hartnup's disease, 23
 head growth, DBS, paediatric dystonia, 240
 head shape, DBS, paediatric dystonia, 240
 head trauma. *see* posttraumatic dystonia
 health professionals
 collaboration, 82–83, **83f17.1**, **84f17.2**, 85–86
 dystonia specialist nurses, 85–86
 education of, 250, 437
 hemidystonia, 11, **12t2.1**, **15t3.1**, 20, **20t4.1**
 alternating hemiplegia of childhood, 294
 DBS, 66, 302–03
 direct cortical stimulation, 337
 gamma knife radiosurgery, 326
 head trauma, 21–22, 66
 medication for, 268, 270, **275t54.1**, 420
 thalamotomy, 303, 320
 herodegenerative dystonia, 20, 22–24
 classification, 9–10
 cognitive function, **69t14.1**
 due to other neurologic diseases, 24
 inherited metabolic disorders, 22–23
 mitochondriopathies, 22
 nucleotide-repeats diseases, 24
 storage disorders, 23
 Herz, Ernst, 2–3, **2f1.1**
 heuristic model of motor disturbances, musician's dystonia, 203–04, **204f41.1**
 historical perspectives, 87–91, **87t19.1**, **88f19.1**, **89f19.2**, **89f19.3**, **89f19.4**, **90f19.5**
 BT therapy, 121–22
 classification of dystonia, 9
 DBS, 90, 302–03, 389
 definitions of dystonia, 1–3
 Dystonia Europe, 437
 musician's dystonia, 195–96, 446
 psychogenic dystonia, 217
 rehabilitation, 256
 stereotactic surgeries, 315–16, 363
 surgical treatments for dystonia, 299, 311
 thalamotomy, 315–16, 363, 389
 holistic treatment, rehabilitation, 249
 home-based training programmes, writer's cramp, 411
 homework sheets, BT clinics, 190, **191f39.1**
 homocysteinaemia, 23
 human serum albumin, BT products, 125
 Huntington's disease (HD)
 DBS, 383
 herodegenerative dystonia, 24
 pallidotomy outcomes, 319
 tetrabenazine, 272
 hyperbilirubinaemia, cerebral palsy dystonia, 229
 hyperkinetic movements, cerebral palsy dystonia, 379
 hypermobility, risk factors for dystonia, 247
 hypokinesia, 430. *see also* bradykinesia
 DBS adverse effects, 397, 398–99
 hypotonia, 1
 hypoxanthine-guaninephosphoribosyltransferase enzyme deficiency, 69
 IAB Academy, 82–83. *see also* Interdisciplinary Working Group for Movement Disorders
 idiopathic dystonia. *see* isolated dystonia
 iliopsoas muscle, BT injections, 146
 imaging. *see also specific modalities*
 DBS programming, 400
 indications for DBS, 353
 small children with dystonia, 238
 stereotactic surgeries, 321–22, **323f60.4**
 immobilisation techniques. *see also* finger splinting
 cervical dystonia, 253
 musician's dystonia, 210
 rehabilitation, 254
 writer's cramp, 410, **412t77.1**
 immunology
 BT therapy, 133–35, **133t28.1**, **134f28.1**, 174
 secondary dystonia, 20–21
 implantable pulse generators (IPGs), 241, **241f48.1**, 400–02
 incidence, primary dystonia, 27. *see also* epidemiology
 incobotulinumtoxinA, 99, **115**, 123, 179–80
 blepharospasm, 168–69
 cervical dystonia, 160
 injection schemes, 154
 musician's dystonia, 206
 properties of formulation, **129t27.1**
 indications for therapy. *see* patient selection criteria
 individualised medicine, 56, 381, 383
 infection
 DBS, 240, 241
 pallidotomy outcomes, 319
 secondary dystonia, 20–21
 information provision. *see* patient education
 informed consent, paediatric dystonia, 239–40
 infraspinatus muscle, BT injections, 143
 inherited dystonia, classification, **12**, **12t2.1**, **13f2.2**
 inherited metabolic disorders, 22–23
 inhibition systems
 animal models of dystonia, 50
 cannabinoids, 420
 DBS, functional mechanisms, 347–48
 DBS, paediatric dystonia, 235
 future directions for study, 428, 430
 non-invasive brain stimulation, 414–15
 pathophysiology, 40–42, 247
 psychogenic dystonia, 224, 225
 injection schemes/techniques, BT injections, 154–58. *see also* muscular anatomy; ultrasonography for BT injections
 arm dystonia, 157–59
 axial dystonia, 157, **159t32.7**

Index

- injection schemes/techniques,
 BT injections (*cont.*)
 blepharospasm, 168–69, 168f34.1
 bruxism, 182, 183, 183f37.1, 184f37.2
 BT clinics, 190–92
 cervical dystonia, 154–55
 cranial dystonia, 155, 156–55
 dose modifiers, 154t32.1
 focal hand dystonias, 180
 musician's dystonia, 200, 209t42.1
 oromandibular dystonia, 156–58, 169–70, 170f34.2
 writer's cramp, 155–56, 157
 injury. *see* peripheral injury;
 posttraumatic dystonia
 innervation, cervical dystonia, 311, 311t59.1
 in-plane technique,
 ultrasonography, 149
 inter-rater reliability, assessment
 scales, 75
 interdisciplinary collaboration,
 82–83, 83f17.1, 84f17.2, 85–86
 Interdisciplinary Working Group
 for Movement Disorders
 (IAB), 82–83, 83f17.1, 84f17.2
 internal consistency, assessment
 scales, 75
 International Dystonia
 Symposia, 303, 435
 International Neurological
 Reunion, Paris, 2
 International Physical Activity
 Questionnaire, 248–49
 international registries, DBS,
 secondary dystonias, 384
 intra-rater reliability, assessment
 scales, 75
 intracerebral haemorrhage
 (ICH), treatment
 complications, 318–19, 404
 intracranial pressure, secondary
 dystonia, 21t4.3
 intradural denervation/
 intradural rhizotomy,
 299–300, 307–08, 311. *see also* selective peripheral
 neurotomy
 intrathecal baclofen. *see*
 baclofen
 invertebrate models, DYT1
 dystonia, 49
 ion channels. *see also* calcium
and sodium ion channels
 BT, 103
 drugs/pharmaceuticals, 265
 genomics, 60
 Ipsen. *see* abobotulinumtoxinA
 IQ, 68–69
 ischaemic stroke. *see* stroke
 Isenheim altarpiece, artistic
 depictions, 93
 isolated (formerly primary)
 dystonia, 15–18, 19f3.2
 age at onset/bodily
 distribution, 15–17, 19f3.2
 classification, 9, 11, 12, 13
 cognitive function, 69t14.1
 DBS, 234, 352–54, 356–58, 385–86
 diagnosis, 15t3.1
 Dystonia Coalition pilot
 project, 442tIII.3
 examples, 16f3.1
 genetics, 17, 18t3.2, 53–54, 55t10.1
 incidence and prevalence, 27, 28t5.1
 non-motor features, 17–18
 pallidotomy outcomes,
 319, 320t60.1, 321f60.3, 322t60.2
 psychiatric manifestations in
 dystonia, 70t14.2
 item response theory (IRT), 80, 442tIII.3
 Jankovic Rating Scale (JRS), 77
 Kayser-Fleischer rings, 12, 23
 KCTD17 (potassium channel
 tetramerisation domain)
 gene, 55t10.1
 kinaesthesia, 42
 KinesioTaping, for writer's
 cramp, 410
 knock-in/ knock-out rodent
 models, 50–51. *see also*
 mouse models
 Korea, BT products, 100
 lacosamide, 293t56.1
 language function, 68
 Lanzhou Institute, China, 100
 LAP1 (leucine aminopeptidase)
 gene, 60
 laryngeal dystonia
 age at onset/bodily
 distribution, 17
 assessment scales, 76t15.1
 classification, 10, 11
 epidemiology, 28t5.1, 30
 risk factors, 30
 ultrasonography targets, BT
 injections, 153t31.1
 lateral cerebellum, non-invasive
 brain stimulation, 417
 lateral pterygoid muscle (LPM)
 bruxism, 182, 183, 184f37.2
 BT injections, 141
 laterocollis, selective peripheral
 denervation, 310–11, 313f59.1
 L-dopa-induced dyskinesias
 (LIDs), 280–81. *see also*
 levodopa treatment
 learning-based sensorimotor
 training (LBST), 210, 411, 431
 Lederman, Richard, 196
 leg dystonia. *see* limb dystonia
 Leksell stereotactic frames,
 thalamotomy, 364
 Lesch–Nyhan disease (LND)
 cognitive function, 69, 69t14.1
 herodegenerative
 dystonia, 22–23
 oromandibular dystonia, 169
 psychiatric manifestations in
 dystonia, 70t14.2
 lesioning/ablative surgery.
see stereotactic ablative
 surgeries
 levator angularis oris muscle, BT
 injections, 140
 levator labii superioris muscles,
 BT injections, 140
 levator inhibition. *see* apraxia of
 eyelid-opening
 levator scapulae muscle (LS)
 BT injections, 142
 innervation, 311, 311t59.1
 selective denervation, 306, 307, 307f58.2, 310–11
 ultrasonography targets, BT
 injections, 153t31.1
 levodopa treatment, 264–65, 278, 280–81, 284t55.1. *see also*
 dopa-responsive dystonia
 cognitive function, 69
 history of treatment, 88–90
 LICI (long-interval intracortical
 inhibition), 40–41
 life stressors. *see* stress triggers
 limb dystonia
 BT injections, 143–48, 157–59
 BT therapy, 113
 epidemiology, 28t5.1, 29–30
 future directions for study, 431
 risk factors, 30
 ultrasonography targets,
 BT injections, 150f31.1, 153t31.1
 lipid metabolism, DYT1
 dystonia, 60
 lisuride, 264–65
 LL complex *Clostridium*
botulinum strains, 120, 122, 123, 124–25
 LND. *see* Lesch–Nyhan disease
 Lodi, Giovanni Agostino da, 92
 long-interval intracortical
 inhibition (LICI), 40–41
 long-latency afferent inhibition
 (LAI), 41
 long-term potentiation
 (LTP), 43–44
 longus colli muscle, postural
 correction, 254, 254f50.2
 low-back pain, BT therapy, 116t25.1
 lower-limb dystonia. *see* limb
 dystonia
 Lubag disease. *see* X-linked
 dystonia-parkinsonism
 LULL1 antibody, 60
 lumbricals muscles, BT
 injections, 145
 magnetencephalography (MEG),
 writer's cramp, 411
 magnetic resonance-guided DBS
 surgery, 404
 magnetic resonance-guided
 focused ultrasound, 326
 magnetic resonance-guided
 stereotactic surgery, 324–26, 326f60.6. *see also* functional
 magnetic resonance
 magnetoencephalography-
 pallidal DBS, functional
 mechanisms, 346
 major depressive disorder
 (MDD), 71. *see also*
 depression
 male gender. *see* gender
 Manual Ability Classification
 System (MACS), 229
 MAO inhibitors (MAOIs), 281, 284t55.1
 Marsden, C. David, 9, 92
 classification of the
 dystonias, 3
 definitions of dystonia, 3
 musician's dystonia, 195
 Marsden cocktail, 266
 masseter muscle
 BT injections, 141, 156–58
 bruxism, 183, 183f37.1
 oromandibular dystonia,
 170f34.2
 ultrasonography targets, BT
 injections, 153t31.1
 master cell banks, *Clostridium*
botulinum strains, 124
 MCS. *see* motor cortex
 stimulation
 MD. *see* myoclonus dystonia
 MDD. *see* major depressive
 disorder
 mechanical measures, history
 of treatment, 87, 87t19.1, 89f19.3
 medial pterygoid muscle, BT
 injections, 141
 medial pterygoid muscle
 (MPM), bruxism, 183
 medication. *see* pharmaceuticals
 medium spiny neurons
 (MSNs), 50
 MEG (magnetencephalography),
 writer's cramp, 411
 Meige syndrome
 age at onset/bodily
 distribution, 16
 classification, 9
 DBS, 360–61
 definitions, 167
 drug treatment, 265
 stereotactic surgeries, 321
 treatment options, 360
 Melbourne Assessment of
 Upper Limb Function
 (MAULF), 239
 memory deficits, 68. *see also*
 cognitive function
 Menkes, John H. 435

- mentalis muscle, BT injections, 140, 155, 156–58
 Menuhin, Yehudi, 195
 MEPs. *see* motor-evoked potentials
 Messerschmidt, Franz Xaver, 94, 95f20.4
 metabolic disorders, herodegenerative dystonia, 22–23
 metacarpophalangeal joint, musician's dystonia, 203
 metachromatic dystrophy, 23
 methylmalonic acid disease, 23
 mexiletine, 265
 mice. *see* mouse models
 microelectrode recording (MER), 345–46
 microvascular decompression (MVD), 301
 migraine, BT therapy, 115–16
 mind–body dualism, psychogenic dystonia, 217
 mitochondrial disorders, 22, 23
 molecular mechanisms
 BT therapy, 102–04, 113f24.1, 116–17, 117f25.1, 128–30
 and classification of the dystonias, 14
 DBS, 348–49, 369
 tetraabenazine, 272, 273f54.2
 monocarboxylate transporter type 8 (MCT8) deficiency, 294
 monogenic dystonias, genetics, 55t10.1
 mood factors. *see also* depression
 DBS complications, 405
 indications for DBS, 353, 386
 motor cortex, inhibition systems, 41
 motor cortex stimulation (MCS), 336–38, 337t61.1, 414–15
 functional MRI, 335, 339f61.3
 intraoperative EMG, 337f61.1
 rating scales, 336, 339t61.3
 stimulation parameters/results, 338t61.2
 three-dimensional reconstruction, 338f61.2, 339f61.3
 motor-evoked potentials (MEPs)
 non-invasive brain stimulation, 414–15
 pathophysiology, 43f8.1
 psychogenic dystonia, 225
 motor network model of dystonia, 32–34, 32f6.1
 mouse bioassay, BT products, 122–23, 130
 mouse models
 cerebellar dystonias, 33
 dopa-responsive dystonia, 51
 DYT1 dystonia, 49–51, 60
 DYT11 dystonia, 51
 DYT12 dystonia, 51
 nuclear membrane budding, 60
 phenotypic models, 51
 tottering mouse mutant, 33, 64
 mouse units (MU), BT, 122, 130, 154
 movement disorders, historical terminology, 2
Movement Disorders journal, 303
 MR. *see* functional magnetic resonance; magnetic resonance
 MR1 (major histocompatibility complex class I) gene, 55t10.1, 56, 292–93
 Mueller, Howard J., 124
 multi-unit activity (MUA), DBS, 345–46
 multidimensional approaches, rehabilitation, 249
 multidisciplinary. *see* interdisciplinary collaboration
 multifocal dystonia, genetics, 55t10.1
 multiple sclerosis, secondary dystonia, 20–21
 muscarinic acetylcholine receptors (mAChRs), 268
 muscle relaxants, 265. *see also* baclofen; benzodiazepines; relaxation
 muscle selection, focal hand dystonias, 179
 muscle surgery, history of treatment, 90
 muscular anatomy, BT injections, 139
 facial muscles, 139–41
 lower limb, 146–48
 neck muscles, 142–43
 upper limb, 143–46
 muscular anatomy, selective peripheral denervation, 306–07, 310
 muscular ultrasonography targets, BT injections, 153t31.1
 musculoskeletal deformities, impact of childhood dystonia, 238
 musician's dystonia (MD), 195, 446–47. *see also* embouchure dystonia
 aetiology, 198–99, 202–05
 artists with dystonia, 94–95
 BT therapy, 206–09, 207f42.1, 208f42.2, 209t42.1
 brain stimulation techniques, 211–12
 cannabinoids, 422, 422t79.1
 choking under pressure, 202, 203, 204
 dynamic stereotypes, 202–03, 204
 dynamic systems theory, 258–59
 epidemiology, 178–79
 focal dystonia, 203
 growth of published research, 196f40.1
 heuristic model of motor disturbances, 203–04, 204f41.1
 historical perspectives, 195–96
 instrument-specific issues, 207–08
 motor control loss/motor fatigue, 202, 203
 non-invasive brain stimulation, 415
 overuse injury, 202, 204
 pathophysiology, 44–45
 patient characteristics, 206–07
 pedagogical retraining, 210–11
 phenomenology, 196–200
 phenotypes, 197, 197f40.2, 198
 prevention, 204–05
 rehabilitation, 257, 257f51.1
 risk factors, 203
 stereotactic surgeries, 320–21
 thalamic DBS, 390
 treatment outcomes, 208–09, 209t42.1
Musicians With Dystonia organisation, 196
Musicians With Dystonia programme, 447
MyDystonia App, 439
 Myobloc. *see* rimabotulinumtoxinB
 myoclonus dystonia (MD), 22, 427
 animal models, 51
 cognitive function, 69, 69t14.1
 DBS, 234, 368–70
 genetics, 55t10.1, 56, 234, 368, 427
 genomics, 59
 psychiatric manifestations, 70t14.2, 71
 thalamic DBS, 390
 myofascial pain syndromes, BT therapy, 116t25.1
 myotomy/myectomy, historical perspectives, 300–01
 nasalis muscle, BT injections, 140, 155
 NBIA. *see* neurodegeneration with brain iron accumulation
 Neck Disability Index, 248–49
 neck muscles, BT therapy, 114–13, 142–43, 152f31.3
 neck pain, BT therapy, 116t25.1
 neck strain, 247
 nervous system pathology, classification of the dystonias, 12, 12t2.1. *see also* central nervous system
 network disorder, dystonia as, 345, 352, 420
 neuroacanthocytosis, 24, 383
 Neurobloc. *see* rimabotulinumtoxinB
 neurodegeneration with brain iron accumulation (NBIA), DBS, 234, 240, 383
 neurodegenerative disease
 DBS, paediatric dystonia, 234
 genomics, 59
 oromandibular dystonia, 169
 therapeutic failure in DBS, 395
 neuroimaging. *see* imaging
 Neurological Institute, Columbia, 447
 neurological manifestations, classification of the dystonias, 12
 neuronal ceroid lipofuscinosis, 23
 neuronal energy metabolism, secondary dystonia, 21t4.3
 neuron-specific enolase (NSE), 50
 neuromyography, BT, 103–04
 neuropathic pain, direct cortical stimulation, 335
 neurophysiologic mapping, stereotactic surgeries, 322–23
 neurophysiology, future directions for study, 428–29
 neuroplasticity. *see* plasticity changes
 neuropsychological studies, cognitive function, 68
 neurotomy. *see* selective peripheral denervation
 neurotoxin-associated proteins (NAPs), 99
 neurotransmitter systems studies, imaging, 38
 neurotransmitter/enzyme deficiencies, drug treatment, 279–80, 280f55.1, 282–83. *see also* specific neurotransmitters
 next-generation sequencing, 53
 nicotinic acetylcholine receptors, 268
 Niemann–Pick disease, 23
 9q34 gene, 55t10.1
 non-alcohol-responsive myoclonus-dystonia, 55t10.1
 non-invasive brain stimulation (NIBS), 414–17, 416t78.1, 429. *see also* transcranial direct current stimulation; transcranial magnetic stimulation
 non-motor features of dystonia, 68, 72
 cognitive function, 68–70, 69t14.1
 pain, 72
 primary dystonia, 17–18
 psychiatric manifestations, 70–71, 70t14.2
 sensory features, 72
 sleep disturbances, 72
 non-primary dystonia. *see* secondary dystonia
 norepinephrine transporter (NART), 272

Index

- nuclear membrane budding, proteomics, 60
 nucleic acid contamination, BT products, 123
 nucleotide-repeats diseases, 24
 nurses, specialist, 85–86
 Nursing and Midwifery Council (NMC) code of conduct, 86
- obliquus capitis inferior muscle innervation, 311, **311t59.1**
 selective denervation, 310, 312
 obliquus capitis superior muscle innervation, 311, **311t59.1**
 selective denervation, 310, 311
 obsessive compulsive disorder, 70–71, **70t14.2**, 257
 occipital muscles, selective denervation, 310
 occupational therapy. *see also* rehabilitation
 history of treatment, 90
 writer's cramp, 409–13, **412f77.2**, **412t77.1**
 ocular symptoms. *see* ophthalmological symptoms
 Oculinum. *see* onabotulinumtoxinA
 off-plane technique, ultrasonography, 149, **150f31.1**, **152f31.3**
 olanzapine, 265
 onabotulinumtoxinA, 99, 100, **115**, **121**, **122**
 blepharospasm, 168
 bruxism, 183
 cervical dystonia, 160, **162t33.1**
 focal hand dystonias, 179–80
 historical perspectives, 99, **121**
 injection schemes, 154
 musician's dystonia, 206
 potency, 122
 properties of formulation, **129t27.1**
 Online Mendelian Inheritance in Man (OMIM), 59
 onset characteristics/abrupt onset, psychogenic dystonia, 218, 224
 ophthalmological symptoms
 blepharospasm, 17
 classification of the dystonias, 12
 Oppenheim, Hermann, 15, 53–54, 427–28
 classification of the dystonias, 9
 definitions of dystonia, 1–2
 history of treatment, 87
 musician's dystonia, 195
 Oppenheim dystonia, **55t10.1**. *see also* DYT1 dystonia
 opponens pollicis muscle, BT injections, 145–46
- orbicularis oculi muscle, BT injections, 139, 155, 168–69, **168f34.1**
 orbicularis oris muscle, BT injections, 140–41, 155, 168–69
 oromandibular dystonia. *see also* Meige syndrome
 age at onset/bodily distribution, 17
 assessment scales, **76t15.1**
 BT therapy, 156–58, 169–70, **170f34.2**
 classification of the dystonias, 11
 clinical presentation, 169
 definitions of dystonia, 3
 drug treatment, 265
 epidemiology, **28t5.1**, 30
 peripheral trauma, 67
 sleep disturbances, 72
 outcome assessment. *see* clinical outcome assessments
 overflow dystonia, 224
 overuse injury, musician's dystonia, 202, 204
 oxcarbazepine, **293t56.1**
- paediatric dystonia, 238
 aetiology, 238
 DBS. *see* deep brain stimulation, paediatric dystonia
 developmental implications, 238
 diagnosis, 239
 epidemiology, 238
 imaging, 238
 impact of childhood dystonia, 238
 spasticity, 238–39
 pain
 DBS, paediatric dystonia, 235
 impact of childhood dystonia, 238
 non-motor features, 72
 psychogenic dystonia, 219, 224
 pain, neuropathic, direct cortical stimulation, 335
 paired associative stimulation (PAS), 43–44, 347, 348
 pallidotomy, 315, **317f60.1**. *see also* globus pallidus internus; stereotactic ablative surgeries
 historical perspectives, 315–16
 imaging, 321–22
 indications, 319–21
 MR-guided stereotactic laser ablation, **326f60.6**
 outcomes, 319–21, **320t60.1**, **322t60.2**
 Parkinson's disease analogues, 316–18, **318f60.2**
 radiofrequency lesion generation procedure, **325f60.5**
- pantothenate kinase-associated neurodegeneration (PKAN), 69, **69t14.1**
 neurodegeneration with brain iron accumulation, 234
 oromandibular dystonia, 169
 psychiatric manifestations in dystonia, **70t14.2**, 71
 parkinsonism, DBS induced, 397–99, **398f74.1**, 405. *see also* rapid-onset dystonia-parkinsonism; X-linked dystonia-parkinsonism
 Parkinson's disease dystonia, 3
 as analogue for dystonia, 316–18, **318f60.2**
 anticholinergic agents for, 270
 direct cortical stimulation, 335
 herodegenerative dystonia, 24
 paroxysmal exercise-induced dyskinesias, 294
 psychiatric manifestations in dystonia, 71
 parotid gland, BT injections, 141
 paroxysmal dystonia/dyskinesias, 3
 differential diagnosis, 219
 drugs/pharmaceuticals, 292–94, **293t56.1**
 genetics, **55t10.1**
 temporal patterns, 11
 paroxysmal exercise-induced dyskinesia (PED), 293–94
 paroxysmal non-kinesigenic dyskinesias (PNKD), 292–93
 pathophysiology of dystonia, 40, 45
 basal ganglia
 pathophysiology, 345
 bio-psycho-social model, 247
 and DBS, 352, 398–99
 drugs/pharmaceuticals, 268
 focal hand dystonias, 178–79
 inhibition systems, 40–42
 plasticity, 43–44
 sensorimotor integration/abnormalities, 42–43, **43f8.1**
 task specificity, 44–45
 three-dimensional brain reconstruction, **44f8.2**
 patient advocacy, 435–36, 437, **441tIII.2**
 patient education
 Dystonia Europe, 437
 Dystonia Medical Research Foundation, 436
 role of dystonia specialist nurses, 86
 patient expectations, DBS, 405–06
 patient selection criteria
 DBS, 233, 352–53, 386
 selective peripheral denervation, 311
 stereotactic surgeries, 318–21
 tetrabenazine, 272–73
 thalamotomy, 363–64
- pectoralis major muscle
 BT injections, 143, 157–59
 denervation, 308
 pedagogical retraining, musician's dystonia, 210–11
 PEOD (primary early-onset dystonia), 27
 percussion instruments, musician's dystonia, **208f42.2**
 perfectionism, risk factors for dystonia, 195, 203, 257
 performance anxiety, musicians, 202
 Performing Arts Medicine, 446–47
 pergolide, 281
 perinatal encephalopathy, 20
 peripheral denervation. *see* selective peripheral denervation
 peripheral injury, 67. *see also* posttraumatic dystonia
 psychogenic dystonia, 221, **222t44.2**
 secondary dystonia, 21
 periventricular leucomalacia (PVL), 238–39
 periventricular white matter disorders (PWM), 238–39
 persistent dystonia, temporal patterns, 11
 personality disorders, psychogenic dystonia, 218
 PET. *see* positron emission tomography
 pharmaceuticals, 263, 265–66. *see also specific drugs*
 blepharospasm, 167
 cerebral palsy
 dystonia, 229–31
 combination treatments, 266
 dopa-responsive dystonia, 280–82, **284t55.1**
 future directions for study, 430–31
 history of treatment, **87t19.1**, 88–90
 myoclonus dystonia syndrome, 368
 paroxysmal dystonia, 292–94, **293t56.1**
 posttraumatic dystonia, 66
 secondary dystonia, 20, **21t4.3**
 spasmodic dysphonia, 174
 tremor, 64–65
 withdrawal effects, 68–69, 231, 354, 421
 pharmacology
 baclofen, 230
 BT products, 128–31, **129f27.1**, **129t27.1**, 133–34
 gamma-aminobutyric acid, 45
 tetrabenazine, 272, **273f54.1**
 Phase III. Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trial, 115–16

- phasic movements, cerebral palsy dystonia, 379
- phenomenology
- musician's dystonia, 196–200
 - psychogenic dystonia, 219
- phenotypes/phenotypic models
- animal models of dystonia, 51
 - classification of the dystonias, 13f2.2
 - Dystonia Coalition pilot project, **442tIII.3**
 - heterogeneity, 238
 - musician's dystonia, 197, 197f40.2, 198
 - primary dystonia, 17, 19f3.2
- phenytoin, **293t56.1**
- physical examination, psychogenic dystonia, **219t44.1**, 220–21
- physical fitness levels, risk factors for dystonia, 247
- physicians. *see* health professionals
- physiology. *see* pathophysiology of dystonia
- physiotherapy. *see* rehabilitation
- piano players, 94–95, 195, 207, 208f42.2, 212. *see also* musician's dystonia
- cannabinoids, 420, 421f79.1
 - pedagogical retraining, 211
- piriformis muscles, BT injections, 146
- PKAN. *see* pantothenate kinase-associated neurodegeneration
- placebo effect
- future directions for study, 431
 - psychogenic dystonia, 221
- plasticity changes
- animal models of dystonia, 50, 60
 - BT therapy, 109
 - DBS, 235, 345, 347–48
 - Dystonia Coalition pilot project, **442tIII.3**
 - future directions for study, 428, 430
 - musician's dystonia, 204, 210
 - non-invasive brain stimulation, 414–15
 - pathophysiology, 43–44
 - pathophysiology of dystonia, 268
 - psychogenic dystonia, 225
 - rehabilitation, 250
- platysma muscle, BT injections, 142, 155, 156–58
- PLD. *see* proportion of life lived with dystonia
- PLOD (primary late-onset dystonia), 29–30
- 'Porteuse d'eau au bord du Nil' (Castres), artistic depictions, 93
- positron emission tomography (PET), 36, 37, 43f8.1, 45
- post-lesional dystonia, 218
- posterior ramisectomy, 312
- postinfection syndrome. *see* infection
- posttraumatic dystonia, 21–22, 66–67. *see also* peripheral injury
- DBS, 66, 382
- pallidotomy outcomes, 319
- primary late-onset dystonia
- risk factors, 30
 - thalamic DBS, 390
- postural correction, 254, 254f50.2
- postures, dystonic, 310–11
- potency, BT products, 122–23
- power grip, musician's dystonia, 199
- precision grip, musician's dystonia, 199
- pregnancy, drug treatment, 283
- premotor cortex (PMC), non-invasive brain stimulation, 336, 415–17
- prevalence. *see also* epidemiology
- primary dystonia, 27, **28t5.1**
 - secondary dystonia, 30
 - tardive dyskinesia and tardive dystonia, 372
 - tremor, 63
- prevention, musician's dystonia, 204–05
- primary dystonia. *see* isolated dystonia
- primary early-onset dystonia (PEOD), 27
- primary focal dystonia, psychiatric manifestations, 70
- primary late-onset dystonia (PLOD), 29–30
- primates, evolutionary perspectives, 199, 199f40.3
- prion proteins, animal models of dystonia, 50
- PRKRA (protein activator of interferon-induced protein kinase) gene, **55t10.1**, 56
- procerus muscle, BT injections, 139
- process validation, BT products, 125, 126
- progenitor toxin complexes (PTC), BT therapy, 102
- programming, DBS, 400–02
- progressive supranuclear palsy, 3, 185
- pronator quadratus muscle, BT injections, 145
- pronator teres muscle, BT injections, 145, 155–56, 157–59
- proportion of life lived with dystonia (PLD), 239. *see also* symptom duration
- propranolol, 64
- proprioception, rehabilitation, 250, 254
- protein composition, BT products, 123
- proteomics, DYT1 dystonia, 60–61, 61f11.1
- PRRT2 (proline-rich transmembrane protein 2) gene, **55t10.1**, 56, 292, **293t56.1**
- pseudodystonias, 10, 13
- pseudo-failure, 394. *see also* deep brain stimulation (therapeutic failure)
- psychiatric perspectives, 220. *see also* psychotherapy
- cognitive function, 68
 - non-motor features, 70–71, **70t14.2**
 - psychogenic dystonia, 225
 - tardive dyskinesia and tardive dystonia, 373
- psychogenic dystonia. *see* functional/psychogenic dystonia
- psychometric approaches, rating scales, 79–80
- psycho-social factors, rehabilitation, 248, 249–50
- psychotherapy. *see also* psychiatric perspectives
- history of treatment, **87t19.1**, 88
 - psychogenic dystonia, 221
- pterygoid muscle, 141
- BT injections, 169–70
- oromandibular dystonia, 156–58, 170f34.2
- PTPS (6-pyruvoyltetrahydropterin synthase) deficiency, 279–80, 280f55.1, 281, 282–83, **284t55.1**
- public awareness, role of DMRF, 436
- purification, BT products, 123, 124–25
- Purkinje neurons, 33, 64
- putamino-pallido-thalamic neuronal circuit, 66
- putty, therapeutic, 410
- pyramidal tract activity, intrathecal baclofen, 230
- quadriceps femoris muscle, BT injections, 146
- quality of life (QoL), 68
- cerebral palsy dystonia, 380
 - DBS, paediatric dystonia, 233
 - rehabilitation, 247, 248, 249
- radiofrequency lesioning/ablation
- in situ* DBS leads, 324
 - stereotactic surgeries, 323–24, **325f60.5**
 - tardive dyskinesia and tardive dystonia, 372–73
- Ramazzini, Bernardino, 94
- randomised controlled trials (RCTs)
- cervical dystonia, BT therapy, **162t33.1**
 - non-invasive brain stimulation, 417
 - rehabilitation, 249, 250
- rapid-onset dystonia-parkinsonism (RDP)
- animal models, 51
 - cognitive function, 69, **69t14.1**
 - differential diagnosis, 218
 - genetics, 51, **55t10.1**, 56, 60, 294
 - genomics, 60
 - psychiatric manifestations, **70t14.2**, 71
- Rasch measurement theory (RMT), 79–80
- rating scales, 75–77, **76t15.1**. *see also* Burke–Fahn–Marsden Dystonia Rating Scale; Toronto Western Spasmodic Torticollis scale and other specific scales by name
- BT clinics, 190
 - cerebral palsy dystonia, 229, 379–80
 - cervical dystonia, 160
 - DBS, paediatric dystonia, 239
 - Dystonia Coalition pilot project, **442tIII.3**
 - rehabilitation, 248–49, 252–53
 - theoretical basis, 79–81
- RCTs. *see* randomised controlled trials
- RDP. *see* rapid-onset dystonia-parkinsonism
- record-keeping, BT clinics, 190
- rectus capitis muscle
- innervation, 311, **311t59.1**
 - selective denervation, 310, 311, 312
- recurrent laryngeal nerve (RLN), 172
- reflex sympathetic dystrophy, 21, 67
- regional pain syndrome, 21
- registries, international, 384
- rehabilitation, 250
- assessment, 248, 252–53
 - bio-psycho-social model, 247–48, **248t49.1**
 - cervical dystonia, 252–55, 253f50.1, 254f50.2
 - clinical presentation, 247
 - DystonieNet recommendations, 445
 - focal hand dystonia, 256–59, 257f51.1
 - future directions for study, 431
 - goal-setting, 249–50
 - history of treatment, 90
 - psycho-social intervention strategies, 250
 - quality of life, 247, 248, 249
 - rating scales, 248–49

Index

- rehabilitation (*cont.*)
 sensory and motor
 impairment treatment, 250
 task modification and
 training, 249–50
 treatment principles, 249
 writer's cramp, 409–13,
 412f77.2, **412t77.1**
 relaxation techniques, **87t19.1**
 musician's dystonia, 200
 rehabilitation, 254
 writer's cramp, 411, **412t77.1**
 reliability, assessment scales, 75
 RELN (reelin) gene, **55t10.1**
 Renshaw cells, BT
 therapy, 113
 repetitive movements
 psycho-social factors, 248
 risk factors for dystonia, 247
 repetitive strain injury, 247
 repetitive transcranial magnetic
 stimulation (rTMS),
 musician's dystonia, 211–12
 research gaps/needs. *see* future
 directions for study
 retraining, pedagogical, 210–11
 retrocollis, selective peripheral
 denervation, 311
 Revance, (company) California,
 100, **101t21.3**
 rhizotomy. *see* intradural
 denervation/intradural
 rhizotomy
 rhomboid major muscle, BT
 injections, 143
 Ribera, Jose de, 92–93, 92f20.1
 Richer, Paul, 93
 rimabotulinumtoxinB, 99, 115
 blepharospasm, 168
 cervical dystonia, 160,
162t33.1
 musician's dystonia, 206
 properties of formulation,
129t27.1
 type B BT, 117–18
 risk factors, 247. *see also* stress
 triggers
 antibody-induced therapy
 failure, BT therapy, 134
 musician's dystonia, 203
 perfectionism, 195, 203, 257
 primary late-onset dystonia, 30
 risorius muscle, BT injections,
 140, 155, 156–58
 rodent models, transgenic, 49–
 50. *see also* mouse models
 rotation. *see* torticollis
 safety aspects of treatment. *see*
also side effects
 BT therapy, 120–21, 130–31,
 161
 DBS, 373
 tetrabenazine, 274–78
 Sativex, musician's dystonia, 422,
422t79.1
 scalene muscle complex, BT
 injections, 142, **153t31.1**
 Schantz, Edward J. 121
 Schiele, Egon, 93
 Schumann, Robert, 94–95, 195
 Schwalbe, Walter, 87
 Schweitzer, Albert, 94
 sciatica, BT therapy, **116t25.1**
 Scott, Alan B., 99, 121, 168–69
 scrivener's palsy, 195
 SD. *see* spasmodic dysphonia
 SDS-PAGE (sodium dodecyl
 sulphate polyacrylamide
 gel electrophoresis), 120,
 120f26.1, 121–22, 123
 secondary dystonia, 20–22. *see*
also specific types
 characteristic features, **20t4.1**
 classifications, 9–10, 13, 20,
21t4.3
 DBS, 382–84
 dystonia-plus syndromes, 20,
 22
 pallidotomy outcomes, 319,
 321f60.3, **322t60.2**
 prevalence, 30
 syndromic associations/
 clinical clues, **21t4.2**
 Segawa disease. *see* dopa-
 responsive dystonia
 segmental dystonia
 artistic depictions, 92f20.1,
 93–94, 94f20.2, 95f20.3,
 95f20.4
 cognitive function, **69t14.1**
 DBS, 357–58
 epidemiology, **28t5.1**, 29–30
 psychiatric manifestations,
70t14.2
 selective peripheral denervation,
 306–08, 306f58.1, 307f58.2,
 308f58.3
 cervical dystonia, 310–13,
311t59.1, 313f59.1
 historical perspectives, 90,
 90f19.5, 299–300
 selective serotonin-reuptake
 inhibitors (SRRIs), 430–31
 self-efficacy, rehabilitation,
 250
 Self-Efficacy Scale, 248–49
 self-injury, **70t14.2**, 71
 semimembranosus muscle, BT
 injections, 146
 semispinalis capitis (SSC)
 muscle
 anatomy, 306–07, 306f58.1
 BT injections, 142–43, 150–
 51, **153t31.1**
 innervation, 311, **311t59.1**
 selective denervation, 310,
 311, 312
 semispinalis cervicis (SSCer)
 muscle
 anatomy, 306–07
 innervation, 311, **311t59.1**
 selective denervation, 310,
 311, 312
 semitendinosus muscle, BT
 injections, 147
 sensorimotor impairment
 bio-psycho-social model, 248
 integration, 42–43, 43f8.1,
 44f8.2
 plasticity. *see* plasticity
 rehabilitation, 250, 409–10
 sensorimotor retraining, 431
 sensory cortex, 67
 sensory features of dystonia, 72
 sensory training, writer's
 cramp, 409
 sensory tricks
 blepharospasm, 167
 BT therapy, 107f23.1, 109
 diagnosis of dystonia, 247
 effect on cervical dystonia, 253
 focal hand dystonia, 256–57
 history of treatment, 87,
87t19.1, 89f19.4, 90
 musician's dystonia, 203
 oromandibular dystonia, 169
 psychogenic dystonia, 221, 224
 torticollis, 310
 sepiapterine reductase (SR), 282,
284t55.1, 427
 SEPs. *see* somatosensory evoked
 potentials
 serotonin transporter
 (SERT), 272
 serotype A, botulinum, 120
 BT clinics, 190
 bruxism, 182
 cervical dystonia, 160
 historical perspectives,
 121–22
 musician's dystonia, 206
 pharmacology, 128, 129–30
 serotype B, botulinum, 99, 117–
 18, 120, 128
 BT clinics, 190
 cervical dystonia, 160
 musician's dystonia, 206
 pharmacology, 128
 serotype C, botulinum, 137
 serotype D, botulinum, 137
 serotype E, botulinum,
 137–38
 serotype F, botulinum, 138
 set-shifting deficits, cognitive
 function, 68
 SGCE (sarcoglycan) gene,
55t10.1, 56, 234, 427. *see*
also myoclonus-dystonia
 Short Form-36 Physical Activity
 subscale, 336
 short intracortical inhibition
 (SICI), 40–41
 short-latency afferent inhibition
 (SAI), 41
 shoulder pain, BT therapy,
116t25.1
 side-effects and adverse effects of
 treatment
 BT therapy, 161
 cannabinoids, 420–21
 DBS, 354, 361, 386, 397–99,
 398f74.1, 405
 tetrabenazine, **278t54.3**
 single photon emission
 computed tomography
 (SPECT), 36
 SLC16A2 (glucose transporter
 protein type 1) gene, 53,
55t10.1, 56, 293, 294
 sleep disturbances, non-motor
 features, **70t14.2**, 72
 slowing down techniques,
 writer's cramp, 94, **412t77.1**
 small children with dystonia. *see*
 paediatric dystonia
 SNAP-25 (synaptic protein)
 BT therapy, 112, 115, 117,
 117f25.1, 137–38
 drugs/pharmaceuticals, 292
 SNARE (soluble N-
 ethylmaleimide-sensitive
 fusion attachment protein
 receptor) proteins, 61, 102,
 103–04, 115, 122, 128,
 129–30
 sodium ion channels, 60, 265,
 292
 soleus muscle, BT injections,
 147, **153t31.1**
 soluble N-ethylmaleimide-
 sensitive factor attachment
 receptor. *see* SNARE
 somatosensory cortex
 musician's dystonia, 210
 non-invasive brain
 stimulation, 417
 somatosensory-evoked potentials
 (SEPs), 42–43, 108, 335
 somatotopic representations,
 sensory cortex, 42
 spasmodic dysphonia (SD), 172,
 176
 assessment scales, **76t15.1**
 BT therapy, 173–74, 174f35.1,
 175f35.2
 diagnosis, 172–73
 epidemiology, 172
 surgery, 175–76
 treatment (other than BoT
 therapy), 175
 spasmodic torticollis, 1,
 88f19.1, 89f19.2, 89f19.3.
see also Toronto Western
 Spasmodic Torticollis
 scale
 spastic conditions/spastic
 movement disorders, 20
 BT therapy, 113–12
 IAB Communication
 Calendar, 84f17.2
 small children with
 dystonia, 238–39
 specialist nurses, 85–86
 speech disturbances, stereotactic
 surgeries, 320
 spinal cord effects, BT
 therapy, 106–08
 spinal cord stimulation
 (SCS), historical
 perspectives, 301
 spinocerebellar ataxias, 24

- splenius capitis muscle
 anatomy, 306–07, **306f58.1**
 BT injections, 142, **153t31.1**, 155
 innervation, 311, **311t59.1**
 peripheral denervation, 310–11, 312
 splinting. *see* finger splinting
 spread
 classification of dystonia, 11
 DYT1 dystonia, **18t3.2**
 musician's dystonia, 198
 posttraumatic dystonia, 66
 primary late-onset dystonia, 30
 psychogenic dystonia, 218, 219
 SR (sepiapterin reductase), 282, **284t55.1**, 427
 SSRIs (selective serotonin reuptake inhibitors), 282
 STARDY study, 373
 status dystonicus, DBS, 234–35, 354, 379
 stereotactic ablative surgeries, 315, **317f60.1**, 326–27.
 see also pallidotomy;
 thalamotomy
 complications, 318–19, 320–21, 365–66
 historical perspectives, **87t19.1**, 302
 indications, 318–21, 363–64
 lesion generation, 323–24, **325f60.5**
 MR-guided laser ablation, 324–26, **326f60.6**
 MR-guided focused ultrasound, 326
 outcomes, 319–21, **320t60.1**, **321f60.3**, **322t60.2**
 presurgical screening, 318–19
 radiofrequency ablation *in situ* DBS leads, 324
 tardive dyskinesia and tardive dystonia, 372–73
 stereotactic frames, DBS, 240
 stereotactic surgeries, 316, 318
 sternocleidomastoid muscle
 BT injections, 142, 150–51, **153t31.1**, 155
 cervical dystonia, 252–53, **253f50.1**
 innervation, 311, **311t59.1**
 peripheral denervation, 299, 310–11
 surgical treatments, 311
 storage disorders, herodegenerative dystonia, 23
 stress triggers
 DYT12/rapid-onset dystonia-parkinsonism, 51
 MR-1-related paroxysmal dyskinesias, 292–93
 musician's dystonia, 258
 psychogenic dystonia, 220
 risk factors for dystonia, 247
 spasmodic dysphonia, 173
 stretching, **412t77.1**
 rehabilitation, 250, 254
 writer's cramp, 411
 stringed instruments, musician's dystonia, 207–08, **208f42.2**
 stroke, treatment outcomes, 319, 336–38
 subthalamic nucleus (STN)
 DBS, 385–87
 future directions for study, 430
 historical perspectives, 302
 isolated dystonia, 353
 Meige syndrome, 361
 paediatric dystonia, 233, 235
 programming, 402
 secondary dystonia, 384
 suggestion, role in psychogenic dystonia, 221, 224
 Sully, Samuel, 195
 supinator muscle, BT injections, 145, 155–56
 supraspinatus muscle, BT injections, 143
 surgical treatments for dystonia.
 see also deep brain stimulation;
 selective peripheral denervation;
 stereotactic surgeries
 blepharospasm, 185–86, **186f38.2**, **187f38.3**
 CNS lesioning, 302
 future directions for study, 429–30
 historical perspectives, **87t19.1**, 90–91, 299
 intradural rhizotomy, 299–300
 intrathecal baclofen, 302
 microvascular decompression, 301–02
 myotomy and myectomy, 300–01
 spasmodic dysphonia, 175–76
 spinal cord stimulation, 301
 surround inhibition, 41–42, 198, 224, 414, 415–17, 428. *see also* inhibition systems
 swallowing impairments, 235
 symptom duration
 and DBS, 239, 352, 358, 394
 indications for stereotactic surgeries, 363
 and surgical outcomes, 300
 symptomatic dystonia. *see* secondary dystonia
 synaptic protein. *see* SNAP-25
 synaptic vesicle glycoprotein 2 (SV2), 128–30
 synaptotagmin (Syt), 128–30
 syndrome, dystonia as, 2–3, 20, **21t4.2**
 Syntaxin (company), BT products, 101
 systemic manifestations, classification of dystonia, 12
 systemic metabolism, secondary dystonia, **21t4.3**
 tactile stimuli, effect on cervical dystonia, 253. *see also* sensory tricks
 TAF1 (TATA-box binding protein-associated factor 1) gene, **55t10.1**, 56, 59
 Taira's procedure, peripheral neurotomy, 307–08, **308f58.3**
 tardive dyskinesia (TDk) and tardive dystonia (TDt), 167, 372
 DBS, 372–75, **374t68.1**
 L-dopa induced, 280–81
 pallidotomy outcomes, 319
 prevalence, 30, 372
 tetraabenazine, 274, **277t54.2**
 targeted secretion inhibitors (TSI), BT, 101
 task-based studies, functional imaging, 37–38
 task specificity
 diagnosis of dystonia, 247
 pathophysiology, 44–45
 task-specific focal hand dystonia (TSFHD)
 Dystonia Coalition pilot project, **442t111.3**
 rehabilitation, 256–59
 stereotactic surgeries, 363, **365f66.3**
 TDk/TDt. *see* tardive dyskinesia and tardive dystonia
 teamwork, interdisciplinary, 82–83, **83f17.1**, **84f17.2**, 85–86
 temporal discrimination threshold (TDT), functional dystonia, 225
 temporal patterns, classification of dystonia, 11, **12t2.1**
 temporalis muscle, 182, 183, **183f37.1**
 teres major muscle, BT injections, 143
 test-retest reliability, assessment scales, 75
 tetraabenazine (TBZ), 265, 272, 278, 372
 clinical indications, 272–73
 dosage and safety aspects, 274–78
 efficacy, 273–74, **275t54.1**, **277t54.2**
 history of treatment, 88–90
 mechanism of action, 272, **273f54.2**
 pharmacology, 272, **273f54.1**
 side-effects, **278t54.3**
 tetrahydrobiopterin (BH4), 279–80, 281, 282–83, **284t55.1**
 TH gene, 55, **55t10.1**. *see also* tyrosine hydroxylase
 thalamic DBS, 389–90
 combined with STN targets, 386
 future directions for study, 430
 historical perspectives, 302
 paediatric dystonia, 233, 234
 thalamic radiofrequency lesioning, historical perspectives, 302
 thalamotomy, 315, **317f60.1**, 318, 363, 366. *see also* stereotactic ablative surgeries
 complications, 365–66
 gamma knife radiosurgery, 326
 historical perspectives, 315–16, 363, 389
 imaging, 321–22, **323f60.4**
 indications/patient selection criteria, 320–21, 363–64
 intra-operative set-up, **365f66.3**
 neurophysiologic mapping, 323
 outcomes, 320–21, 364–65
 surgical technique, 364
 ventro-oral nucleus, **365f66.2**
 THAP1 (THAP domain-containing protein 1) gene, 37, 54, **55t10.1**, 59, 234, **442t111.3**. *see also* DYT6 dystonia
 therapeutical putty, writer's cramp, 410
 THP. *see* trihexyphenidyl
 tibialis posterior muscle, BT injections, 147, **153t31.1**
 tics, 3
 tilt of the head. *see* laterocollis tongue, BT injections, 141
 tongue protrusion dystonia, 235
 tonic vibration reflex, 42
 TOR1A (torsinA) gene, 37, 53–54, **55t10.1**, 60, 268, 427. *see also* DYT1 dystonia
 Toronto Western Spasmodic Torticollis scale (TWSTRS), **76t15.1**, 77
 cannabinoids, 420
 cervical dystonia, BT therapy, **162t33.1**
 cervical dystonia, DBS, 356–57
 DBS programming, 402
 direct cortical stimulation, 336
 presurgical screening, 318
 selective peripheral denervation, 313
 therapeutic failure in DBS, 392
 use in BT clinics, 190
 torsinA function. *see* TOR1A (torsinA) gene
 torsion dystonia, 3
 torticollis, 3. *see also* spasmodic torticollis
 artistic depictions, 93–94
 classification of dystonia, 9
 selective peripheral denervation, 310, **313f59.1**
 surgical treatments, historical perspectives, 311
 tottering mouse model, 33, 64
 toxins, animal models of dystonia, 51

Index

- toxicity units (mouse units), BT, 122, 130, 154
- tractography, small children with dystonia, 238–39
- transcranial direct current stimulation (tDCS), 414–17
- musician's dystonia, 211–12
- pathophysiology, 44
- transcranial magnetic stimulation (TMS), 414–17
- musician's dystonia, 211–12
- pathophysiology, 40
- psychogenic dystonia, 225
- small children with dystonia, 238–39
- transcutaneous electrical nerve stimulation (TENS), writer's cramp, 410
- transfer, 256
- transgenic rodent models, 49–50. *see also* mouse models
- trapezius muscle
- BT injections, 142, **153t31.1**, 155–56
- innervation, 311, **311t59.1**
- trauma. *see* posttraumatic dystonia
- tremor, dystonic, 63–65
- anticholinergic agents for, 270
- direct cortical stimulation, 335
- thalamic DBS, 390
- treatment, 64–65
- tremor associated with dystonia (TAWD), 64
- triceps muscle, BT injections, 143, 155–56
- trigeminal neuralgia, BT therapy, **116t25.1**
- trihexyphenidyl (THP), 160, 236, 263–64, 268–69, 270
- Tsui Scale, **76t15.1**, 77, 160
- cervical dystonia, **162t33.1**, 163–64
- use in BT clinics, 190
- TUBB4a (beta-tubulin) gene, **55t10.1**, 56, 59
- TWSTRS. *see* Toronto Western Spasmodic Torticollis scale
- Twisted* film, 436
- Two Hands* film, musician's dystonia, 196
- two-hit hypothesis, motor network model, 33
- types. *see* serotypes, botulinum toxins
- tyrosine hydroxylase (TH), 427. *see also* TH gene
- animal models of dystonia, 50, 51
- dopa-responsive dystonia, drug treatment, 279–80, **280f55.1**, 283, **284t55.1**
- ultrasonography (US), for BT injections, 149–51
- cervical dystonia, 164
- injection needles used, **151f31.2**
- neck muscles, **152f31.3**
- target muscles, **153t31.1**
- upper limb, **150f31.1**
- ultrasound, MRI-guided focused (MRgFUS), 326
- Unified Dystonia Rating Scale (UDRS), 76, 229, 318
- upper-limb dystonia. *see* limb dystonia
- validity, assessment scales, 75
- ventral intermediate thalamic nucleus (VIM)
- DBS, 368–69, 370, 386, 389, 390
- thalamotomy, 389
- ventrolateral (VL) thalamic nucleus, 315, 430
- ventro-oral (Vo) thalamic nucleus, thalamotomy, **365f66.2**
- vesicle-associated membrane protein (VAMP), 115, 117–18, 137, 138
- vesicular monoamine transporter, 265
- vibration-induced illusion of movement, 42
- violin players, musician's dystonia, 207–08, **208f42.2**
- visual symptoms, classification of dystonia, 12
- Vocal Performance Questionnaire, **76t15.1**
- Voice Handicap Index, **76t15.1**
- voice therapy, spasmodic dysphonia, 175
- voltage-gated ion channels. *see* ion channels
- Volterrano, artistic depictions, 92
- wellbeing, cerebral palsy dystonia, 380. *see also* quality of life
- whiplash injury, cervical dystonia, 67
- whispering dystonia, genetics, **55t10.1**, 56
- white matter lesions, small children with dystonia, 238–39
- whole-exome/whole-genome sequencing (WES/WGS), 427–28
- Wilson, Kinnier, 2, 69–70
- Wilson's disease, 1, 2
- aetiology, 263
- classification of dystonia, 12
- cognitive function, 69–70, **69t14.1**
- herodegenerative dystonia, 23
- psychiatric manifestations in dystonia, **70t14.2**, 71
- Wisconsin Card Sorting test, 68
- woodwind instruments, musician's dystonia, 208, **208f42.2**
- working cell banks, *Clostridium botulinum* strains, 124
- World Health Organization, assessment scales, 75
- wound closure, DBS, paediatric dystonia, 241
- writer's cramp, **16f3.1**, 178, 179
- aetiology, 178
- age at onset/bodily distribution, 15–16
- artists with dystonia, 94–95
- bio-psycho-social model, **248t49.1**
- BT therapy, **150f31.1**, 155–56, **157**, 179–80
- classification of dystonia, 9, 11
- DBS, 357
- definitions of dystonia, 1, 3
- epidemiology, 178–79
- ergonomic devices, **412f77.2**
- finger splinting, **410f77.1**
- flexion patterns, **178f36.1**
- with mixed flexion and extension, **179f36.2**
- non-invasive brain stimulation, 415
- occupational therapy, experimental, 409–13, **412t77.1**
- pathophysiology, 44–45, 178–79
- peripheral trauma, 67
- stereotactic surgeries, 320–21, 363
- symptoms/natural history, 178
- thalamic DBS, 390
- treatment (other than BoT therapy), 179
- Xeomin. *see* incobotulinumtoxinA
- X-linked dystonia-parkinsonism, 56
- cognitive function, 68–69, **69t14.1**
- genetics, **55t10.1**
- psychiatric manifestations, **70t14.2**, 71
- zolpidem, 264
- zygomaticus major muscle, BT injections, 140